Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

Yun Wang, Chunhua Li, Robert Gale, Qi Liang, Neil Kay, Victoria Wang, Qianqian Huang, Yiling Song, Weida Wang, Yang Liang

Blood (2025) 146 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2025-2132

Published: 2025

Journal Articles

B-like natural killer cells related to the epstein-barr virus infection present an adaptive immune phenotype and stronger killing activity in lymphomas

Blood (2025) 146 (Supplement 1): 1769.

https://doi.org/10.1182/blood-2025-1769

Published: 2025

Journal Articles

Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial

Xiaoqin Chen, Yun Wang, Zhijian Liang, Weida Wang, Hua Wang, Bingyi Wu, Yang Liang, Zhongjun Xia

Blood (2025) 146 (Supplement 1): 5829.

https://doi.org/10.1182/blood-2025-5829

Published: 2025

Journal Articles

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Min Yang, Yang Liang, Guorong Wang, Baijun Fang, Luqun Wang, Songfu Jiang, Yafei Wang, Heng Mei, Wei Yang, Yanjuan He, Wei Wang, Haichao Zhang, Houguo Wang, Jie Jin, Wenming Chen

Blood (2025) 146 (Supplement 1): 5822.

https://doi.org/10.1182/blood-2025-5822

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

FLT3/ITD-driven noncanonical STAT1 S727 phosphorylation upregulates CD276, mediating CD8positive- T cell exhaustion and immune evasion in AML

Yun Wang, Shuzhao Chen, Shutong Liu, Zhijian Liang, Chunhua Li, Yang Liang

Blood (2025) 146 (Supplement 1): 771.

https://doi.org/10.1182/blood-2025-771

Published: 2025

Journal Articles

Single-cell RNA-seq uncovers that plerixafor can mobilize more monocyte progenitor cells and enhance the activating graft immune status in multiple myeloma autologous transplantation.

Chenfei Liu, Yuanbin Song, Yang Liang, Jingxia Xu, Lu Lu, Lezong Chen, Chunlei Dai, Tao Chen, Langqi Wang, Yongshuai Jiang, Xianyuan Li, Honghong Yan, Xumiao Zhang, Xiao Zhang, Yinglin Su, Zhenzhen Chou

Blood (2025) 146 (Supplement 1): 7698.

https://doi.org/10.1182/blood-2025-7698

Published: 2025

Journal Articles

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations

Blood (2025) 146 (Supplement 1): 3788.

https://doi.org/10.1182/blood-2025-3788

Published: 2025

Journal Articles

Dynamic monitoring of circulating tumor DNA for real-time risk assessment in early-stage natural killer/t-cell lymphoma

Zegeng Chen, Huang He, Xiaojie Fang, Yuke Tian, Huawei Weng, Liqun Zou, Hongqiang Guo, Hongyu Zhang, Yang Liang, Huangming Hong, Tongyu Lin

Blood (2025) 146 (Supplement 1): 1745.

https://doi.org/10.1182/blood-2025-1745

Published: 2025

Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2025-5677

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Blood (2025) 146 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2025-5122

Published: 2025

Journal Articles

Safety and Efficacy of Luspatercept in Low-Risk Myelodysplastic Neoplasms with Anaemia

Yang Liang, Yuanbin Song, Chenfei Liu, Lu Lu, Bingyi Wu, Weida Wang, Shuzhao Chen, Lezong Chen

Blood (2024) 144 (Supplement 1): 6713.

https://doi.org/10.1182/blood-2024-207749

Published: 2024

Journal Articles

Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Blood (2024) 144 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2024-200952

Published: 2024

Journal Articles

Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study

Dong Liang, Demei Feng, Qiaoli Wang, Shenrui Bai, Min Zeng, Bo Lu, Xiaoqing Li, Zhiqiang Sun, Jianyun Li, Huanhuan Zhou, Jialu Zhang, Xiaoqin Chen, Zhongjun Xia, Yang Liang, Hua Wang

Blood (2024) 144 (Supplement 1): 7064.

https://doi.org/10.1182/blood-2024-204519

Published: 2024

Journal Articles

Safety and Efficacy of Selinexor Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma: A Multi-Center, Single-Arm, Phase Ib/II Trial

Xiaoqin Chen, Yun Wang, Weida Wang, Hua Wang, Bingyi Wu, Yang Liang, Zhongjun Xia

Blood (2024) 144 (Supplement 1): 7025.

https://doi.org/10.1182/blood-2024-204564

Published: 2024

Journal Articles

Efficacy and Safety of Carfilzomib-Based Regimens in a Real-World Clinical Practice: Insights from China

Dong Liang, Demei Feng, Yang Liang, Hua Wang

Blood (2024) 144 (Supplement 1): 7875.

https://doi.org/10.1182/blood-2024-203304

Published: 2024

Journal Articles

A Retrospective Analysis of Orelabrutinib-Containing Regimen for Marginal Zone Lymphoma

Hua Wang, Yang Liang, Dong Liang, Demei Feng

Blood (2024) 144 (Supplement 1): 6332.

https://doi.org/10.1182/blood-2024-203319

Published: 2024

Journal Articles

Efficiency and Safety of Pegylated Filgrastim Combined with Plerixafor in Multiple Myeloma Autologous Hematopoietic Stem Cells Mobilization

Chenfei Liu, Yuanbin Song, Yang Liang, Lu Lu, Weida Wang, Bingyi Wu

Blood (2024) 144 (Supplement 1): 7118.

https://doi.org/10.1182/blood-2024-207526

Published: 2024

Journal Articles

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Huafeng Wang, Xudong Wei, Yang Liang, Jianyu Weng, Wenjuan He, Chunkang Chang, Suning Chen, Hongbing Ma, Zi Chen, Lichuang Men, Lihui Liu, Xiaohong Tian, Zhang Zhang, Danhua Cong, Dajun Yang, Yifan Zhai, Jie Jin

Blood (2024) 144 (Supplement 1): 3202.

https://doi.org/10.1182/blood-2024-205371

Published: 2024

Journal Articles

Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology

Yujun Dai, Xue-Ping Li, Yang Liang

Blood (2024) 144 (Supplement 1): 192.

https://doi.org/10.1182/blood-2024-200714

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

B-like natural killer cells related to the epstein-barr virus infection present an adaptive immune phenotype and stronger killing activity in lymphomas

Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

FLT3/ITD-driven noncanonical STAT1 S727 phosphorylation upregulates CD276, mediating CD8positive- T cell exhaustion and immune evasion in AML

Single-cell RNA-seq uncovers that plerixafor can mobilize more monocyte progenitor cells and enhance the activating graft immune status in multiple myeloma autologous transplantation.

Dynamic monitoring of circulating tumor DNA for real-time risk assessment in early-stage natural killer/t-cell lymphoma

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Safety and Efficacy of Luspatercept in Low-Risk Myelodysplastic Neoplasms with Anaemia

Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study

Safety and Efficacy of Selinexor Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma: A Multi-Center, Single-Arm, Phase Ib/II Trial

Efficacy and Safety of Carfilzomib-Based Regimens in a Real-World Clinical Practice: Insights from China

A Retrospective Analysis of Orelabrutinib-Containing Regimen for Marginal Zone Lymphoma

Efficiency and Safety of Pegylated Filgrastim Combined with Plerixafor in Multiple Myeloma Autologous Hematopoietic Stem Cells Mobilization

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only